Blair R. Leavitt

Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018.

Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018.

Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018.

Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018.

Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018.